The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Prices of newly launched drugs in the U.S. have more than doubled from 2021 to 2024, driven by rare disease therapies, ...

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The US Food and Drug Administration (FDA) has cleared Grifols' investigational new drug (IND) application to initiate a Phase ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

On May 16, 2024, the CDE’s official website announced that the Application would be reviewed via the priority review and approval process. This marks the fourth sac-TMT indication to go through the ...

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...